About this trial
Chronic lung diseases such as pulmonary fibrosis and chronic obstructive pulmonary disease (COPD) can lead to pulmonary hypertension. This serious complication involves increased pressure in the lung vessels, which strains the heart and worsens outcomes. Since the early symptoms are unclear, diagnosis often occurs too late, underscoring the need for simple, noninvasive methods of early detection.
A key driver of the disease is vascular remodeling, which involves the narrowing and stiffening of blood vessels. This process involves changes in the extracellular matrix, particularly in the understudied basement membrane. Our project examines how specific components, especially non-classical collagens, change during disease progression. As vessels remodel, detectable fragments enter the bloodstream, potentially creating a molecular fingerprint of the disease.
By analyzing lung tissue and blood samples, the investigators aim to identify non-invasive biomarkers for earlier diagnosis, better patient classification, and more personalized treatment.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
None
Disqualifiers
Presence of other lung diseases
Signs of infection, such as pneumonia, pulmonary tuberculosis, or pleural effusions.
Trial population
Patients undergoing lung transplantation with COPD or PF, with or without associated PH or PAH. Outpatient cohort with COPD or PF, with or without associated PH or PAH.
Trial design
Cohort
Prospective
Treatments tested in this trial
Not listed
Trial groups
Trial outcomes
Primary outcomes
Analysis of collagen fragments
The fragments will be measured in the plasma, serum, or tissue using an enzyme-linked immunosorbent assay (ELISA), mass spectrometry, or single-cell analysis.
Secondary outcomes
Disease severity assessment
The assessment of disease severity will be based on the associated clinical data and compared to the generated collagen fingerprint, as determined by the primary outcome.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Medical University of Graz
Lead sponsor
Medical University of Vienna
Collaborator